Skip to main content

Company News

October 23, 2024

Global Response to the 2024 Mpox Outbreak: Need for Enhanced Diagnostics and Equitable Resource Distribution

Fast, effective diagnostics are crucial in the identification of individuals infected with monkeypox (MPXV); a potentially fatal virus previously known as monkeypox. The outbreak was declared a public health emergency of international concern by the World Health Organization (WHO) in August 2024, just two years after a similar occurrence in 2022. Many top health officials have called for a coordinated international response to curb the spread and save lives. Drawing on this experience, University of Alabama at Birmingham Professor and epidemiologist David O. Freedman, contributes insights into managing outbreaks in a post-pandemic world.
  • December 08, 2022

    Cell and Gene Therapies: bioMérieux partners with NecstGen

    bioMérieux and NecstGen, collaborate to accelerate the development of Cell and Gene Therapies (CGT) through the provision of ‘state of the art’ and rapid quality and safety testing technologies that will allow safe and effective advanced therapeutics production.
  • October 27, 2022

    20 years of collaboration in the fight against infectious diseases.

    For 20 years, bioMérieux and the Hospices Civils de Lyon (HCL) have been collaborating in an innovative public/private research partnership. Joined in 2016 by Claude Bernard Lyon 1 University, the three institutions are working to figure out the mechanisms of immunity in order to develop diagnostic tests.

Follow us on Socials for more news!